Mediterranean diet and physical activity decrease the initiation of cardiovascular drug use in high cardiovascular risk individuals: A cohort study
Author
Publication date
2021-03Abstract
Our aim was to assess whether long-term adherence to a Mediterranean diet (MedDiet) and leisure-time physical activity (LTPA) were associated with a lower initiation of cardiovascular drug use. We studied the association between cumulative average of MedDiet adherence and LTPA and the risk of cardiovascular drug initiation in older adults at high cardiovascular risk (PREvención con DIeta MEDiterránea trial participants) non-medicated at baseline: glucose-lowering drugs (n = 4437), antihypertensives (n = 2145), statins (n = 3977), fibrates (n = 6391), antiplatelets (n = 5760), vitamin K antagonists (n = 6877), antianginal drugs (n = 6837), and cardiac glycosides (n = 6954). One-point increases in MedDiet adherence were linearly associated with a decreased initiation of glucose-lowering (HR: 0.76 [0.71–0.80]), antihypertensive (HR: 0.79 [0.75–0.82]), statin (HR: 0.82 [0.78–0.85]), fibrate (HR: 0.78 [0.68–0.89]), antiplatelet (HR: 0.79 [0.75–0.83]), vitamin K antagonist (HR: 0.83 [0.74; 0.93]), antianginal (HR: 0.84 [0.74–0.96]), and cardiac glycoside therapy (HR: 0.69 [0.56–0.84]). LTPA was non-linearly related to a delayed initiation of glucose-lowering, antihypertensive, statin, fibrate, antiplatelet, antianginal, and cardiac glycoside therapy (minimum risk: 180–360 metabolic equivalents of task-min/day). Both combined were synergistically associated with a decreased onset of glucose-lowering drugs (p-interaction = 0.04), antihypertensive drugs (p-interaction < 0.001), vitamin K antagonists (p-interaction = 0.04), and cardiac glycosides (p-interaction = 0.01). Summarizing, sustained adherence to a MedDiet and LTPA were associated with lower risk of initiating cardiovascular-related medications.
Document Type
Article
Document version
Published version
Language
English
Keywords
Dieta mediterrània
Exercici
Medicaments
Glucosa
Antihipertensius
Estatines (Medicaments cardiovasculars)
Fibrats
Antiagregants
Vitamines K -- Inhibidors
Antianginosos
Glucòsids cardíacs
Pages
14 p.
Publisher
MDPI
Is part of
Antioxidants, 2021, 10(3): 397
Grant agreement number
info:eu-repo/grantAgreement/MINECO/ISCIII/OBN17PI02
info:eu-repo/grantAgreement/MINECO/ISCIII/CB06/03/0019
info:eu-repo/grantAgreement/MINECO/ISCIII/CB06/03/0028
info:eu-repo/grantAgreement/MINECO/ISCIII/CD17/00122
info:eu-repo/grantAgreement/SUR del DEC/SGR/2017BP00021
info:eu-repo/grantAgreement/SUR del DEC/SGR/2017SGR222
info:eu-repo/grantAgreement/MEFPU/FPU/FPU17/00785
This item appears in the following Collection(s)
Rights
© L'autor/a
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/